More possibilities from Rivastigmine to new potential agents on treating Alzheimer’s disease: In silico study

Zhi-Gang Sun1,2*, Qing Yuan1 and Yu-Shun Yang1

1School of Life Sciences, Nanjing University, Nanjing 210023, PR China
2Central Laboratory, Linyi Central Hospital, Linyi 276400, Shandong, PR China

Abstract
Alzheimer’s disease (AD) is one of the most hazardous and frequent chronic neurodegenerative disease around the world. Though several hypotheses have been raised, four in five of the FDA certified drugs for treating AD were acetylcholinesterase inhibitors. This work raised more possibilities on substituent-positions and conformations from the most potent AChEI Rivastigmine. The molecular docking indicated the probable advantage of the para-position and the S-conformation. The key interactions with residues including TYR121 and HIS440 were recognized in the visualized binding patterns. The information raised here was valuable for future modifications and designs of AChEIs.

Introduction
Along with the development of the modern world, advanced medicinal and therapeutic conditions have encouraged longevity to be the common sense [1]. Concomitantly, the usual defined diseases for elder population, have forced the researchers to face the fact that they are occurring with higher percentages and stretching their claws to younger people [2,3]. Among them, Alzheimer’s disease (AD) is of course one of the most hazardous and frequent, which ruined the capabilities of remembering recent things, organizing language, distinguishing orientations and controlling mood [4,5]. AD is a widely known chronic neurodegenerative disease and it caused a majority of dementia cases (over 60%) [6,7]. On the contrary, the cause of AD is still poorly revealed. Since the major phenomena are amyloid beta (Aβ) deposits, tau protein abnormalities and neuronal death, several hypotheses have been raised accordingly [8-10]: 1) Genetic cause, mainly the mutations in genes encoding amyloid precursor protein (APP) and presenilins 1 and 2 [11]; 2) Cholinergic hypothesis, the most typical one with the most currently available drugs based [12-14]; 3) Amyloid hypothesis, the currently leading opinion in this field but the two developed vaccines Bapineuzumab and Solanezumab both failed the Phase III clinical trials [15-18]; 4) Tau hypothesis, the most accepted target following the amyloid with potential agents on the promotion of Tau's decomposition and the inhibition of its accumulation or phosphorylation [19-21]; 5) Other hypotheses including inflammation, aluminium, smoking and gum diseases [22-25]. In spite of the anti-amyloid vaccine’s failures, the very recent study also questioned the rationality of inhibition Tau because its multiple functions [26]. Thus, acetylcholinesterase inhibitors (AChEI) are still the down-to-earth choices of the patients of AD.

Despite Memantine Hydrochloride, other four FDA certified drugs (Figure 1) are all AChEIs, including Tacrine, Donepezil, Galantamine and Rivastigmine [27-30]. Tacrine lost its market because of its hepatotoxicity. Donepezil and Galantamine are both reversible inhibitors, indicating limited treatment effect thus being recommended for the early and moderate period of AD. Only Rivastigmine is the pseudo-irreversibility inhibitor, which can prolong the existing time of acetylcholine thus protect the conduction of neural signals. An extra inhibition site of Rivastigmine may be Butyrylcholinesterase (BuChE), another possible target of treating AD. Developing new trails on AChEIs from Rivastigmine is a meaningful and practical approach for curing AD and even other neurodegenerative disease.

In this work, we extended the possibilities of Rivastigmine from two dimensions, substitution site and steric conformation. By investigating the binding patterns of extended choices into the protein structure of AChE, we attempted to reveal one corner of the iceberg on developing deeper and further achievements in AD treatment (Figure 1).

Materials and methods
According to the basic structure of Rivastigmine, we considered the meta- (original), ortho- and para- substituent situations to develop new molecules. Meanwhile, the opposite conformations were also involved. The studied molecules were listed in Figure 2. Then their conformation optimizing process was conducted by energy minimization via CHARMM force field. In order to guarantee the final conformations, obey the rule of energy minimized, the iteration rounds were set as 5000, which was far more than the real requirement. After that, we checked the consistency of the designed ones and the optimized ones to avoid reversal.

Molecular docking simulation was performed by the CDOCKER project of Discovery Studio software (Accelrys, USA). The crystal structures of AChE (PDB Code: 1GQR) was selected from the RCSB

Received: December 21, 2018; Accepted: January 28, 2019; Published: February 01, 2019

*Correspondence to: Zhi-Gang Sun, School of Life Sciences, Nanjing University, Nanjing 210023, PR China, E-mail: zhugangsuny@nju.edu.cn

Key words: Alzheimer's disease, acetylcholinesterase inhibitors, rivastigmine, substituent position, conformation, molecular docking
consider the binding situations into AChE, Rivastigmine was not the best interacted one. The result was interesting that if simply heating target temperature and the cooling steps are 5000 with 300.

The four FDA certified AChEIs

Rivastigmine

Figure 1. The four FDA certified AChEIs

Figure 2. The expansion of Rivastigmine

Protein Data Bank (http://www.rcsb.org). The protein preparation procedure followed the standard protocol. Before docking, the original ligand and water molecules were deleted from the protein crystal structure. And the polar hydrogen was added to the cleaned proteins. The binding site were defined from the same site of Rivastigmine. The binding site was checked to keep the suitable radius of the sphere (0.5-10 nm) to increase the relatively reliable of the model. For a second time, CHARMM force field was used to complete the docking using the CDOCKER program with the random generated ligand conformations and a half-flexible receptor. Basic steps were as follows:

First, the ligands conformations in series are generated by high temperature molecular dynamics with various random seeds. Second, random orientations of the conformations are subsequently created by translating the center of the ligand to a specified position within the receptor active site and making a series of random rotations with calculated softened energy. Then the orientation is kept until reaching a specified limit. The process repeats before either obtaining the desired number of low-energy orientations or reaching the maximum number of the test times of bad orientations. Third, all orientations are subjected to simulated annealing molecular dynamics. The temperature is heated up to a high temperature then cooled to the target temperature. A final energy minimization of the ligand in the rigid receptor using non-softerned potential is then conducted. Finally, the CHARMM energy (interaction energy plus ligand strain) and the interaction energy alone are figured out for each final pose. The poses are sorted according to CHARMM energy and the top scoring (most negative, thus favorable to binding) poses are restored. The whole kinase domain defined as a receptor and the site sphere is selected based on the original ligand binding location, then the original ligand is removed, and the ligands prepared are placed during the molecular docking procedure. In the simulated annealing method, the heating steps are 2000 with 700 of heating target temperature and the cooling steps are 5000 with 300 cooling target temperature. For each ligand, ten final poses are saved according to their dock score rank. The pose with the lowest energy is chosen as the top one. The pattern analysis is subsequently performed.

Results and discussion

Since the binding site was defined from the original one of Rivastigmine, we thought the original ligand Rivastigmine (S1) should be the best interacted one. The result was interesting that if simply consider the binding situations into AChE, Rivastigmine was not the best choice. As presented in Table 1, we took the minus values of the interaction energy and complex energy. Thus, the larger the values were, the lower the energy was, then the easier the binding would happen or the more stable the complex was. Though the data base was not large, there were still some hints for future researches. First, although both the substituent positions and conformations were important factors, the former seemed more essential due to larger change in steric situations. Both the R and S conformations of para-substituted compounds suggested better interaction with AChE. Second, when we only compared the substituent positions, we could reach the order of para-> (”>” meant “better than”) meta -> ortho- in both conformations. This result inferred that the steric hindrance might block the acetylcholine-mimic function of AChEIs, thus retaining a relative free terminal would be necessary in designing such inhibitors. Third, if we only compare the conformations, the obvious fact was S-> R- in all positions. This might be the real desire of AChE binding. Subsequently, with all the hints involved, could the top hits be more potential than Rivastigmine? The answer was positive but not definite. For the two candidates S3 and R3, they both had some doubts yet. For R3, an obvious problem was that its complex energy was higher than Rivastigmine. That means, even it could realize the easier interaction with the target enzyme, it would also separate in a shorter period. Since AChEIs usually attempted to stick with AChE longer to allow the passing of acetylcholine, R3 seemed conflict with this basic demand. For S3, it was closer to Rivastigmine and provided better parameters in both interaction energy and complex energy. Even all the conditions seemed that S3 could be a more potent hit, further investigations should be conducted step by step to verify its real performances. Because easier interaction and longer binding period might cause other problems such as neurological disorders or a different type of nerve disease. Anyway, the good news was that para-substituted trails could be taken into consideration in future modifications and designs to enrich the backbones of AChEIs.

To visualize the binding patterns of the studied compounds, we presented the 2D maps in Figure 3. Though Rivastigmine was presupposed in other works to decompose from ester group, we took the original status of the studied compounds directly into the active site of AChE to evaluate their initial binding situations. As shown in Figure 3, a major difference between S-conformations and R-conformations was the categories of key interactions. The S-conformations preferred direct hydrogen bonds and sometimes indirect π-σ interactions, whereas the R-conformations all employed π-π or π-cation interactions. According to the reports, if Rivastigmine decomposed, the binding would be weakened to two π-π interactions with TRP84 and PHE330 respectively. Thus, the original status here seemed to indicate better interactions. By retaining the same hydrogen bond with TYR121 with the same pattern and introducing more hydrogen bond with HIS440, S3 and R3 suggested more potential binding pattern than Rivastigmine. The failure of the other three candidates could also be inferred by the binding patterns. R1 lost all potential hydrogen bonds. S2 and R2 seemed to be rotated or reversed in the binding site as their key interactions did not appear at the same positions. The above results were cheerful because the recommended compound S3 was still in similar pattern with Rivastigmine, which enhanced the reliability of

Table 1. The interaction energy and complex energy of the compounds into AChE

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>39.8686</td>
<td>33.4468</td>
<td>R1</td>
<td>39.6957</td>
<td>31.7529</td>
</tr>
<tr>
<td>S2</td>
<td>39.7678</td>
<td>32.3533</td>
<td>R2</td>
<td>39.6621</td>
<td>33.0382</td>
</tr>
<tr>
<td>S3</td>
<td>41.3823</td>
<td>34.3766</td>
<td>R3</td>
<td>41.0413</td>
<td>32.0519</td>
</tr>
</tbody>
</table>
the molecular docking simulation. Thus, the future modification can be cautiously carried out consulting these key interactions.

Conclusion

In summary, more possibilities on substituent-positions and conformations from Rivastigmine were revealed. The molecular docking indicated that the para-position might be the orientation of future modification and the S-conformation should be retained. The key interactions with residues including TYR121 and HIS440 should be treated with extra caution in the future design plans. The information raised in this work might lead to further investigation of AChEIs and even corresponding therapeutic approaches in treating Alzheimer's disease.

References

Sun Z (2019) More possibilities from Rivastigmine to new potential agents on treating Alzheimer’s disease: In silico study

24. Bondy SC (2016) Low levels of aluminum can lead to behavioral and morphological changes associated with Alzheimer’s disease and age-related neurodegeneration. Neurotoxicology 52: 222-229. [Crossref]
26. Qiang L, Sun XH, Austin TO, Muralidharan H, Jean DC, et al. (2018) Tau does not stabilize axonal microtubules but rather enables them to have long labile domains. Curr Biol 28: 2181-2189. [Crossref]